Conavi Medical Announces Results From Its Annual General Meeting of Shareholders and Adoption of Amendments to Omnibus Equity Incentive Plan

About this update from Conavi Medical Corp.

[{"type":"text","content":"Conavi Medical Announces Results From Its Annual General Meeting of Shareholders and Adoption of Amendments to Omnibus Equity Incentive Plan\n\n\n\n TORONTO, April 01, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Corp.\n \n (TSXV: CNVI; OTCQB: CNVIF)\n \n (“\n \n Conavi Medical\n \n ” or the “\n \n Company\n \n ”), a commercial stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures, announced today the results of its annual general meeting of shareholders held virtually on March 31, 2025 (the “Meeting”), as well as the adoption of amendments to the Company’s Stock Option Plan.\n \n\n A total of 30,075,712 common shares were voted in connection with the Meeting, representing approximately 67.97% of the issued and outstanding common shares of the Company.\n \n\n Each of the seven nominees listed in the management information circular of the Company (the “\n \n Circular\n \n ”) dated February 18, 2025, namely, Thomas Looby, Aaron Davidson, Craig Podolsky, Robert D. Mitchell, Susan Allen, Cathy Steiner and Anthony J. Giovinazzo, was elected as a director of the Company for the ensuing year or until his or her successor is elected or appointed.\n \n\n In addition, Conavi Medical reports that an ordinary resolution approving the appointment of PricewaterhouseCoopers LLP as the Company’s auditors for the ensuing year and to authorize the directors to fix the auditors’ remuneration was passed at the Meeting.\n \n\n Further, an ordinary resolution of disinterested shareholders of the Company was passed approving the amendment of the Company’s Omnibus Equity Incentive Plan to remove certain restrictions on the participation of Company directors, executive officers and other insiders (as a group). The Company believes that the removal of the restrictions on insider participation in the Omnibus Equity Incentive Plan (as a group), will provide the Company with greater flexibility to continue to attract, retain and motivate directors and executive officers, while providing room for future growth. Importantly, the total maximum number shares available for issuance under the Omnibus Equity Incentive Plan, being 8,850,017 common shares, has not changed and r...

More updates from Conavi Medical Corp.